Chronic Kidney Disease Market Size, Share, and Industry Analysis, By Drug Class (ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta-blockers, Erythropoiesis-stimulating Agents (ESAs), Diuretics, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction
   1. Research Scope
   2. Market Segmentation
   3. Research Methodology
   4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
   1. Market Drivers
   2. Market Restraints
   3. Market Opportunities
   4. Market Trends
4. Key Insights
   1. Prevalence of Chronic Kidney Disease, By Key Countries, 2023
   2. New Product Launches/ Approvals, By Key Players
   3. Pipeline Analysis, By Key Players
   4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
   5. Impact of COVID-19 on the Market
5. Global Chronic Kidney Disease Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights, and Forecast – By Drug Class
      1. ACE Inhibitors
      2. Angiotensin-II receptor Blockers
      3. Calcium Channel Blockers
      4. Beta-blockers
      5. Erythropoiesis-stimulating Agents (ESAs)
      6. Diuretics
      7. Others
   2. Market Analysis, Insights, and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
   3. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   4. Market Analysis, Insights, and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
6. North America Chronic Kidney Disease Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights, and Forecast – By Drug Class
      1. ACE Inhibitors
      2. Angiotensin-II receptor Blockers
      3. Calcium Channel Blockers
      4. Beta-blockers
      5. Erythropoiesis-stimulating Agents (ESAs)
      6. Diuretics
      7. Others
   2. Market Analysis, Insights, and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
   3. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   4. Market Analysis, Insights, and Forecast – By Country
      1. U.S.
      2. Canada
7. Europe Chronic Kidney Disease Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights, and Forecast – By Drug Class
      1. ACE Inhibitors
      2. Angiotensin-II receptor Blockers
      3. Calcium Channel Blockers
      4. Beta-blockers
      5. Erythropoiesis-stimulating Agents (ESAs)
      6. Diuretics
      7. Others
   2. Market Analysis, Insights, and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
   3. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   4. Market Analysis, Insights, and Forecast – By County/ Sub-region
      1. Germany
      2. U.K.
      3. France
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
8. Asia Pacific Chronic Kidney Disease Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights, and Forecast – By Drug Class
      1. ACE Inhibitors
      2. Angiotensin-II receptor Blockers
      3. Calcium Channel Blockers
      4. Beta-blockers
      5. Erythropoiesis-stimulating Agents (ESAs)
      6. Diuretics
      7. Others
   2. Market Analysis, Insights, and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
   3. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   4. Market Analysis, Insights, and Forecast – By Country/ Sub-region
      1. China
      2. India
      3. Japan
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
9. Latin America Chronic Kidney Disease Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights, and Forecast – By Drug Class
      1. ACE Inhibitors
      2. Angiotensin-II receptor Blockers
      3. Calcium Channel Blockers
      4. Beta-blockers
      5. Erythropoiesis-stimulating Agents (ESAs)
      6. Diuretics
      7. Others
   2. Market Analysis, Insights, and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
   3. Market Analysis, Insights, and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   4. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
10. Middle East & Africa Chronic Kidney Disease Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights, and Forecast – By Drug Class
       1. ACE Inhibitors
       2. Angiotensin-II receptor Blockers
       3. Calcium Channel Blockers
       4. Beta-blockers
       5. Erythropoiesis-stimulating Agents (ESAs)
       6. Diuretics
       7. Others
    2. Market Analysis, Insights, and Forecast – By Route of Administration
       1. Oral
       2. Parenteral
    3. Market Analysis, Insights, and Forecast – By Distribution Channel
       1. Hospital Pharmacies
       2. Retail Pharmacies
       3. Online Pharmacies
    4. Market Analysis, Insights and Forecast – By Country/ Sub-region
       1. South Africa
       2. GCC
       3. Rest of Middle East & Africa
11. Competitive Analysis
    1. Global Market Share Analysis (2023)
    2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
       1. GlaxoSmithKline plc.
       2. Sanofi
       3. AstraZeneca
       4. Amgen Inc
       5. Kissei Pharmaceutical Co., Ltd
       6. Johnson & Johnson Services, Inc
       7. F. Hoffmann-La Roche AG
       8. Sanofi
       9. Teva Pharmaceutical Industries Ltd.
       10. Other Prominent Players